Psychopharm in 2019: Your Ultimate Guide

In this podcast episode, we review the major FDA approvals in psychopharmacology for 2019. We explore brexanolone, bremelanotide, asenapine skin patch, esketamine, and cariprazine.

00:00 Welcome
01:52 Brexanolone (Zulresso)
04:27 Bremelanotide (Vyleesi)
08:31 Transdermal Asenapine (Secuado)
08:58 Esketamine (Spravato)
9:44 Cariprazine (Vraylar)
10:45 Lumateperone (Caplyta)
11:41 Key Points
12:34 Credits & References

Key Points:

- Brexanolone is approved for postpartum depression, given in IV infusion and acts on the as a GABA-A receptor modulator.
- Bremelanotide is for hypoactive sexual desire disorder in premenopausal women. Given in a subcutaneous injection and acts as an agonist on melanocortin receptors.
- Transdermal asenapine is the first skin patch antipsychotic. It is approved for adult schizophrenia.
- Esketamine is administered intranasally for treatment-resistant depression in adults who are taking another antidepressant. It is an NMDA receptor antagonist.
- Cariprazine is now FDA approved for bipolar I depression.
- Lumateperone has just been approved for adult schizophrenia as the first-of-class antipsychotic.

Are you a mental health clinician and want to brush up on psychopharm prescribing? We have what you need! Find the rest of Psychopharmacology Institute podcasts here:

Stitcher:

RSS:

Website: